Clinical trial Recruiting at 23 sites Observational Ages 1 Month and up

Transcatheter closure of perimembranous heart defects across centers

Official title: An International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects

Run by Fondation Hôpital Saint-Joseph · NCT06823635 · Data updated 2026-11-12

This registry tests how well transcatheter closure devices work for perimembranous ventricular septal defects in kids and adults across several international centers.

Quick facts

Study typeObservational
Ages1 Month and up
SexAll
Enrollment2000 (estimated)
SponsorFondation Hôpital Saint-Joseph
Academic / other
Locations25 sites (Copenhagen and 24 other locations)
StatusRecruiting
StartedJanuary 1, 2025
Main results expectedDecember 31, 2026
Study endsJune 30, 2027
Registry record updatedSeptember 8, 2026
Trial IDNCT06823635 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients with PmVSD measuring 3 to less than 20 mm on the LV side, age 1 month or older, weight 5 kg or more, and a left-to-right shunt who undergo transcatheter closure with any commercially available occluder device.

Probably not a fit

Patients with significant comorbidities, inability to attend follow-up, or refusal to share data may not benefit from the information gained.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an international, multicenter, observational registry that collects real-world data on outcomes after transcatheter closure of perimembranous ventricular septal defects (PmVSD). It is non-randomized and retrospective, aiming to assess feasibility, safety, and effectiveness of commercially available occluders, including off-label devices. Data are gathered from multiple sites with follow-up per local protocols to understand procedural success and device performance in a broad patient population. The study includes patients aged 1 month and older with 3–<20 mm defects on the left ventricular side and a left-to-right shunt, who underwent transcatheter closure with any occluder device. No control group is specified, and follow-up adherence is required for eligibility.

Why it matters

Potential benefit: If successful, the registry could clarify which devices provide favorable outcomes for PmVSD closure and inform clinical decisions across diverse patient groups.

How similar studies have gone: Previous reports have demonstrated feasibility and safety signals for transcatheter closures in various VSD contexts; this study aggregates broader international real-world data for PmVSD.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with perimembranous ventricular septal defects (PmVSD) diagnosed by 2D transthoracic echocardiography according to established classification systems, who provided informed consent and underwent transcatheter closure using any commercially available occluder devices (whether specifically designed for this indication or used off-label), with follow-up according to local hospital protocols.
2. Defect size between 3 mm and \<20 mm on the left ventricular side, as measured by 2D echocardiography.
3. Age ≥1 month and body weight ≥5 kg.
4. Left-to-right ventricular shunt.

Exclusion Criteria:

1. Patients or legal guardians refusing the use of personal data for research purposes.
2. Failure to attend any follow-up visit post-discharge.

Where it's running

  • Copenhagen University Hospital, Rigshospitalet
    Copenhagen, Denmark
    Recruiting
  • Magdi Yacoub Heart Foundation
    Cairo, Egypt
    Recruiting
  • Marie Lannelongue Hospital
    Le Plessis-Robinson, France
    Recruiting
  • Lille University Hospital
    Lille, France
    Recruiting
  • Toulouse University Hospital
    Toulouse, France
    Recruiting
  • University Children's Hospital
    Tübingen, Germany
    Recruiting
Show 19 more locations
  • Queen Mary Hospital
    Hong Kong, Hong Kong
    Recruiting
  • Hong Kong Children's Hospital
    Kowloon Bay, Hong Kong
    Recruiting
  • National Cardiovascular Center of Harapan Kita
    Jakarta, Indonesia
    Recruiting
  • Rajaie Cardiovascular, Medical and Research Center
    Tehran, Iran
    Recruiting
  • Hôtel-Dieu de France University Medical Center
    Beirut, Lebanon
    Recruiting
  • Hospital de Especialidades Pediátricas
    Chiapas, Mexico
    Recruiting
  • Silesian Center for Heart Diseases
    Zabrze, Poland
    Recruiting
  • Madinah Cardiac Center MC
    Madinah, Saudi Arabia
    Recruiting
  • Skane University Hospital
    Skåne, Sweden
    Recruiting
  • University Children's Hospital of Zurich
    Zurich, Switzerland
    Recruiting
  • Queen Sirikit National Institute of Child Health
    Nonthaburi, Thailand
    Recruiting
  • Prince of Songkla University
    Songkhla, Thailand
    Recruiting
  • Ankara City Hospital
    Ankara, Turkey (Türkiye)
    Recruiting
  • Koç University
    Istanbul, Turkey (Türkiye)
    Recruiting
  • Umraniye Training and Education Hospital
    Istanbul, Turkey (Türkiye)
    Recruiting
  • SBU Tepecik Training and Research Hospital
    Izmir, Turkey (Türkiye)
    Recruiting
  • Al Jalila Children's Speciality Hospital
    Dubai, United Arab Emirates
    Recruiting
  • University Hospital of Bordeaux
    Bordeaux, France
    Enrolling by invitation
  • The Children's Hospital
    Lahore, Pakistan
    Enrolling by invitation

Study contacts

  • Principal investigator: Raymond N. Haddad, MD, MHSc, PhDc — Marie Lannelongue Hospital, INSERM, UMR-S1358, UP-Saclay
  • Study coordinator: Raymond N. Haddad, MD, MHSc, PhDc
  • Email: raymondhaddad@live.com
  • Phone: +33140942800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.